Chinese research and development platform company WuXi AppTec said today it has acquired HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO).
After completion of acquisition, financial terms of which were not disclosed, HD Biosciences will become a wholly-owned subsidiary of WuXi, and will continue to focus on growing its core competences and providing greater services. The acquisition will further strengthen WuXi's R&D capability from target validation to lead discovery and optimization, improving and expanding WuXi's open-access enabling service platform.
Founded in 2002, HD Biosciences is headquartered in Shanghai with operating facilities in Beijing and San Diego, USA. As a leading biology and preclinical service provider, its plate-based pharmacology & screening capability and AGM based target validation are industry leading platforms with great reputation. The company also provides hit identification, lead discovery, in vivo pharmacology and other related services.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze